Hemostemix Inc. Announces FDA Pre-IND Meeting and NBPP of $960,000
- Written by Reporters
Calgary, Alberta - Newsfile Corp. - December 10, 2025 - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from vascular dementia, angina, ischemic cardiomyopathy, congestive heart...
Read more: Hemostemix Inc. Announces FDA Pre-IND Meeting and NBPP of $960,000

